302a West 12th Street
About ArTara Therapeutics
ArTara is a rare diseases therapeutics company focused on optimizing therapeutics for patients suffering from rare diseases where there is a significant unmet need. Our initial focus is on rare gastrointestinal, metabolic, circulatory and neurological disorders.
CEO: Jesse Shefferman
CMO & President of R&D: Randall Marshall
Please click here for ArTara Therapeutics' job opportunities.
4 articles with ArTara Therapeutics
ArTara Therapeutics Announces Initiation of New Immunology Pipeline Program with TARA-002, a Toll-Like Receptor 4 Agonist, Targeting Rare Lymphatic Malformations
ArTara Therapeutics, a clinical-stage biopharmaceutical company developing treatments for rare diseases with significant unmet therapeutic needs, has initiated development of TARA-002, a toll-like receptor 4 agonist, for the potential treatment of lymphangiomas.
ArTara Therapeutics, a clinical-stage company developing treatments for rare diseases with significant unmet needs, today announces the addition of Julio Casoy, M.D. as Chief Medical Officer.
ArTara Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with FDA on Choline Chloride for Injection for Intestinal Failure Associated Liver Disease (IFALD)
ArTara Therapeuticss, a clinical-stage company developing treatments for rare diseases with significant unmet needs, today announced that it has successfully completed an End-of-Phase 2 meeting with the Food and Drug Administration (FDA) to discuss study of Intravenous (IV) Choline Chloride substrate replacement for patients with Intestinal Failure Associated Liver Disease (IFALD).
Dr. Marshall brings over 30 years’ experience across all aspects of clinical research including translational, Phase 1-3, and post-marketing studies in academia, start-up, and mid-sized biopharmaceutical companies.